scholarly journals Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)

2017 ◽  
Vol 3 (2) ◽  
pp. 113-119 ◽  
Author(s):  
Guido Dalbagni ◽  
Nicole Benfante ◽  
Daniel D. Sjoberg ◽  
Bernard H. Bochner ◽  
S. Machele Donat ◽  
...  
Keyword(s):  
Phase I ◽  
Carcinoma In Situ ◽  
Bacillus Calmette Guerin ◽  
Secondary Carcinoma

Clinical outcome of bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract

2002 ◽  
Vol 9 (12) ◽  
pp. 677-680 ◽  
Author(s):  
HIDEAKI MIYAKE ◽  
HIROSHI ETO ◽  
SHOJI HARA ◽  
HIROSHI OKADA ◽  
SADAO KAMIDONO ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Clinical Outcome ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Bacillus Calmette Guerin

Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: Defining the risk of initial bladder preservation

Urology ◽  
2006 ◽  
Vol 67 (4) ◽  
pp. 737-741 ◽  
Author(s):  
Alan M. Nieder ◽  
Michael A. Simon ◽  
Sandy S. Kim ◽  
Murugesan Manoharan ◽  
Mark S. Soloway
Keyword(s):  
High Risk ◽  
Radical Cystectomy ◽  
Carcinoma In Situ ◽  
Bacillus Calmette Guerin ◽  
Bladder Preservation

Possibile ruolo della citofluorometria (CFM) nel monitoraggio della risposta alla terapia endocavitaria con BCG nel carcinoma in situ della vescica: Monitoring the response to intravesical BCG in the treatment of cis: A possible role of flow cytometry

1995 ◽  
Vol 62 (2) ◽  
pp. 245-247
Author(s):  
M. De Siati ◽  
D. Grassi ◽  
N. Franzolin ◽  
L.S. Azzolina
Keyword(s):  
Flow Cytometry ◽  
Carcinoma In Situ ◽  
Recurrent Disease ◽  
Intravesical Therapy ◽  
Urinary Cytology ◽  
Bacillus Calmette Guerin ◽  
Intravesical Bcg

We report our experience on the treatment of carcinoma in situ (CIS) using intravesical therapy with the Bacillus Calmette-Guerin (BCG). From November 1992 to September 1994, 18 patients received treatment: 6 had associated CIS and 12 secondary CIS. Ploidy of each tumour was determined by flow cytometry. Aneuploidy was found in 12 cases, diploidy in 6 cases. After treatment, a standard bladder mapping was performed: 14 patients showed no evidence of cystoscopic and histological disease and if previously aneuploid, became diploid. 4 patients has recurrent disease after therapy; they were all aneuploid before treatment. One of these showed a persistent aneuploidy, although both voided urinary cytology and histological samples were negative. Six months later, a recurrent CIS was seen at the time of cystoscopy. These results enhance the interest in flow cytometry as a possible predictor of response to BCG in the treatment of CIS.

Urothelial Carcinoma In Situ and Treatment of Bacillus Calmette-Guérin Failures

2019 ◽  
pp. 337-349
Author(s):  
David D’Andrea ◽  
Fred Witjes ◽  
Francesco Soria ◽  
Shahrokh F. Shariat
Keyword(s):  
Urothelial Carcinoma ◽  
Carcinoma In Situ ◽  
Bacillus Calmette Guerin

The efficacy of Bacillus Calmette-Guerin instillation therapy of the upper urinary tract for carcinoma in situ

1999 ◽  
Vol 4 (5) ◽  
pp. 295-297
Author(s):  
T. Hattori ◽  
G. Kimura ◽  
K. Horiuchi ◽  
N. Tsuboi ◽  
K. Yoshida ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Bacillus Calmette Guerin ◽  
Instillation Therapy
Sign in / Sign up

Export Citation Format

Share Document